Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-21
2008-05-06
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S337000, C514S444000, C546S284100, C549S060000, C549S467000
Reexamination Certificate
active
07368477
ABSTRACT:
Compounds of formula I or pharmaceutically acceptable salts thereof are provided:wherein each of R1, R1′, R2, R3, R4, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
REFERENCES:
patent: 2554736 (1951-11-01), Haefliger et al.
patent: 3912743 (1975-10-01), Christensen et al.
patent: 4007196 (1977-02-01), Christensen et al.
patent: 4085225 (1978-04-01), Welle et al.
patent: 4136193 (1979-01-01), Bogeso et al.
patent: 4210754 (1980-07-01), Burkard et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4478836 (1984-10-01), Mouzin et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4536518 (1985-08-01), Welch et al.
patent: RE34712 (1994-08-01), Boegesoe et al.
patent: 5384330 (1995-01-01), Dieter et al.
patent: 5565483 (1996-10-01), Hewawasam et al.
patent: 5668145 (1997-09-01), Bright
patent: 5705646 (1998-01-01), Bright et al.
patent: 5712303 (1998-01-01), Faraci et al.
patent: 5916923 (1999-06-01), Rudolph et al.
patent: 6090803 (2000-07-01), Failli et al.
patent: 6096735 (2000-08-01), Ogawa et al.
patent: 6096736 (2000-08-01), Ogawa et al.
patent: 6194407 (2001-02-01), Failli et al.
patent: 6218397 (2001-04-01), Chen
patent: 6274171 (2001-08-01), Sherman et al.
patent: 6403120 (2002-06-01), Sherman et al.
patent: 6419958 (2002-07-01), Sherman et al.
patent: 6444708 (2002-09-01), Rudolph et al.
patent: 6765008 (2004-07-01), Chen
patent: 6967201 (2005-11-01), Briner et al.
patent: 7045545 (2006-05-01), Briner et al.
patent: 2002/0183395 (2002-12-01), Argentieri et al.
patent: 2004/0029949 (2004-02-01), Argentieri et al.
patent: 2004/0235856 (2004-11-01), McMurray et al.
patent: 2005/0124692 (2005-06-01), Gross et al.
patent: 2005/0143452 (2005-06-01), Gross et al.
patent: 2005/0261347 (2005-11-01), Gross et al.
patent: 2006/0089405 (2006-04-01), Zhou
patent: 2006/0111438 (2006-05-01), Gontcharov et al.
patent: 2006/0241172 (2006-10-01), Zhou et al.
patent: 2006/0241176 (2006-10-01), Stack et al.
patent: 2006/0246551 (2006-11-01), Stack et al.
patent: 2006/0247276 (2006-11-01), Gross et al.
patent: 2006/0252825 (2006-11-01), Tadayon et al.
patent: 2006/0258639 (2006-11-01), Logue et al.
patent: 2006/0258711 (2006-11-01), Rosenzweig-Lipson
patent: 2006/0258712 (2006-11-01), Jacobson
patent: 2006/0258713 (2006-11-01), Rosenzweig-Lipson
patent: 2006/0258714 (2006-11-01), Heffernan et al.
patent: 2006/0258715 (2006-11-01), Jandura et al.
patent: 2006/0258739 (2006-11-01), Ai et al.
patent: WO 2006/000902 (2006-05-01), None
U.S. Appl. No. 11/787,929, Yu, et al.
U.S. Appl. No. 11/787,860, Gontcharov et al.
U.S. Appl. No. 11/726,941, Rosenzweig-Lipson.
U.S. Appl. No. 11/787,663, Mirmehrabi.
Allison, et al.,Am. J. Psychiatry, 156: 1686-96, 1999.
Battegay, et al.,Neuropsychobiology, 13:31, 1985.
Benefield, et al.,Drugs, 32: 313, 1986.
Bishop, et al.,Expert Opin. Ther. Patent, 13: 1691-1705, 2003.
Bundgaard (ed),Design of Prodrugs, Elsevier, Ch. 1(p. 1-92), Ch.4(p. 157-176), Ch.5(p. 177-198), and Ch.6(199-241), 1985.
Bundgaard, et al.,Journal of Drug Delivery Reviews, 8: 1-38, 1992.
Bundgaard,J. of Pharmaceutical Sciences, 77: 285-298, 1988.
Christensen, et al.,Eur. J. Pharmacol., 41: 153, 1977.
Claassen, et al,Brit. J. Pharmacol., 60: 505, 1977.
Cowen, et al.,Human Psychopharmacology, 10: 385-91, 1995.
De Wilde, et al.,Affective Disord., 4: 249, 1982.
Di Giovanni, et al.,Synapse, 35: 53-61, 2000.
Di Matteo, et al.,Neuropharmacology, 37: 265-272, 1998.
Di Matteo, et al.,Neuropharmacology, 38: 1195-1205, 1999.
Dufour, et al.,Int. Clin. Psychopharmacol., 2: 225, 1987.
Fox, et al.,Experimental Neurology, 151: 35-49, 1998.
Hassan, et al.,Brit J. Clin. Pharmacol, 19: 705, 1985.
Lassen,Eur. J. Pharmacol, 47: 351, 1978.
Laursen, et al.,Acta Psychiat. Scand. 71: 249, 1985.
Lowry, et al.,J. Biol. Chem., 193: 265, 1951.
Masand, “Weight gain associated with psychotropic drugs”,Exp. Opin. Pharmacother. I: 377-89, 2000.
Mendell, et al.,N. Engl. J. Med., 348: 1243-55, 2003.
Millan, et al.,Neuropharmacology, 37: 953-55, 1998.
Moret, et al.,Neuropharamacology, 24: 1211-19, 1985.
Robertson, et al.,J. Med. Chem., 31: 1412, 1988.
Rosenzwieg-Lipson, et al., “Antiobesity-like effects of the selective 5-HT2C agonist way”,ASPET abstract, 2000.
Whitaker,Spectrum Life Sciences Decision Resources, 2: 1-9, 2000.
Widder, et al (ed.), Methods in Enzymolgoy,Academic Press, 112:56-67, 1985.
Gao Hong
Gross Jonathan Laird
Stack Gary Paul
Zhou Dahui
Choate Hall & Stewart LLP
Knight Julie Anne
Morris Patricia L.
Robidoux Andrea L. C.
Wyeth
LandOfFree
Benzofuranyl alkanamine derivatives and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzofuranyl alkanamine derivatives and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzofuranyl alkanamine derivatives and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3984283